Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CorMedix (CRMD) Gains from Investment Securities: 2012-2025

Historic Gains from Investment Securities for CorMedix (CRMD) over the last 8 years, with Sep 2025 value amounting to -$4.4 million.

  • CorMedix's Gains from Investment Securities was N/A to -$4.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.0 million, marking a year-over-year change of. This contributed to the annual value of $289,622 for FY2024, which is 45.95% up from last year.
  • Latest data reveals that CorMedix reported Gains from Investment Securities of -$4.4 million as of Q3 2025, which was down 1,860.67% from $247,484 recorded in Q2 2025.
  • In the past 5 years, CorMedix's Gains from Investment Securities registered a high of $25.4 million during Q1 2023, and its lowest value of -$4.4 million during Q3 2025.
  • In the last 3 years, CorMedix's Gains from Investment Securities had a median value of $139,497 in 2024 and averaged $3.2 million.
  • As far as peak fluctuations go, CorMedix's Gains from Investment Securities skyrocketed by 22,513.88% in 2021, and later slumped by 99.62% in 2024.
  • Quarterly analysis of 5 years shows CorMedix's Gains from Investment Securities stood at $6.5 million in 2021, then soared by 34.96% to $8.8 million in 2022, then skyrocketed by 199.67% to $25.4 million in 2023, then crashed by 99.62% to $53,007 in 2024, then spiked by 77.41% to -$4.4 million in 2025.
  • Its Gains from Investment Securities was -$4.4 million in Q3 2025, compared to $247,484 in Q2 2025 and $1.0 million in Q1 2025.